Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Special Report Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorWritten by Jeffrey Neal Johnson. Originally Published: 2/24/2026. 
Key Points - Johnson & Johnson has maintained an impressive streak of increasing its dividend payouts for generations, rewarding long-term shareholders with reliable income.
- Management is driving future expansion by focusing on high-growth pharmaceutical assets and cutting-edge medical technologies, such as robotics.
- Investors looking for shelter from market volatility benefit from a stock that historically moves much less than the broader market indices.
- Special Report: [Sponsorship-Ad-6-Format3]
While the technology sector faces renewed volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different story is unfolding in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech names are finding shelter in a familiar name that is quietly outperforming. Johnson & Johnson (NYSE: JNJ) is trading near all-time highs of roughly $245 per share, creating a divergence that has caught Wall Street's attention. This rally runs counter to the common perception of the healthcare giant as a slow-moving, boring stock. Over the last 30 days, shares have climbed about 14%, significantly outperforming the broader market during a period of uncertainty. That price action suggests institutional money is rotating out of riskier assets and placing a premium on stability, reliable cash flow and consistent execution. Silver: 20% + 68%
Tim Plaehn just found a Silver ETF that delivers monthly income (up to 20% in annual distributions) plus share appreciation (68% in 5 months). The precious metal has become one of the best investments for growth AND income right now. Click here and start to collect in the next 30 days. For investors watching the ticker on Feb. 24, 2026, note a specific calendar event: today is the ex-dividend date for Johnson & Johnson. On the ex-dividend date the stock typically opens lower by the amount of the upcoming dividend, $1.30 per share. That is a mechanical market adjustment—not a reflection of business performance or a sell-off—and for income-focused investors this technical dip often represents an attractive entry point rather than a reason to exit. 64 Years of Unbroken Growth The central case for holding Johnson & Johnson during turbulent markets is its financial stability and role as a portfolio stabilizer. The company belongs to an elite group of equities known as Dividend Kings — firms that have increased their dividend payout for at least 50 consecutive years. Johnson & Johnson has now raised its dividend for 64 consecutive years, a track record that spans multiple recessions, market crashes and geopolitical conflicts. That reliability is rare in a market focused on speculative growth. Currently, the stock yields roughly 2.12%, based on an annual payout of $5.20 per share. While higher yields can be found in bonds or riskier sectors, the appeal here is the blend of growth and safety. The dividend is supported by a substantial liquidity cushion: management projects free cash flow of about $21 billion in 2026. That level of cash generation helps ensure the company can continue to pay shareholders, invest in research and manage legal expenses without heavy borrowing. For risk-averse investors, the most compelling metric may be the stock's beta. Beta measures how much a stock moves compared with the overall market (S&P 500). A beta of 1.0 means the stock moves in lockstep with the market. Johnson & Johnson currently has a beta of about 0.35, meaning it has historically been roughly 65% less volatile than the broader market. When tech stocks swing wildly, J&J tends to hold its ground. Adding JNJ to a tech-heavy portfolio can act as a mathematical shock absorber, dampening overall volatility while maintaining equity exposure. Beyond the Patent Cliff: The Road to $100 Billion A common misconception about safe stocks is that they cannot grow. Johnson & Johnson is disproving that with a strategic pivot that is paying off: management has issued strong guidance for 2026, projecting full-year revenue to cross the $100 billion threshold for the first time in the company's history, alongside adjusted earnings per share (EPS) of about $11.53. This growth is driven by the reinvention of its pharmaceutical division, branded as Innovative Medicine. For years investors worried about a patent cliff after Stelara lost exclusivity in 2025. Typically, when a top drug faces generic competition its revenue collapses. J&J has absorbed that decline through the rise of new blockbuster drugs. Two key assets are driving this resilience: - Darzalex: This oncology powerhouse generates about $14 billion in annual sales and has cemented the company's leadership in treating multiple myeloma, becoming a foundational therapy worldwide.
- Tremfya: Positioned as a successor to Stelara, Tremfya recently released strong three-year remission data for ulcerative colitis. That clinical success supports the company's ability to retain market share in a competitive immunology space.
The Tech in MedTech: High-Margin Technologies The growth story extends beyond pharmaceuticals into the MedTech division, which has shifted to focus on high-growth, high-margin technologies. A prime example is the integration of Shockwave Medical, acquired to modernize the cardiovascular portfolio. Shockwave uses intravascular lithotripsy (IVL) technology — sonic pressure waves that safely break up calcified plaque in arteries, similar to how kidney stones are treated. This is a substantial upgrade over traditional angioplasty balloons. By owning this technology, Johnson & Johnson has secured a high-growth asset that complements its existing heart pump and surgical businesses. Additionally, the company is advancing in robotics. The submission of its Ottava robotic surgical system for FDA approval signals intent to compete directly in the expanding soft-tissue robotics market. These high-tech devices typically carry higher profit margins and create sticky relationships with hospital systems, providing a long-term earnings tailwind beyond consumables and basic surgical tools. Addition by Subtraction: The Orthopedics Strategy To sustain growth and improve margins, management is reshaping the corporate structure. A major development is the potential separation of the DePuy Synthes orthopedics business. Originally planned as a spin-off, recent reports indicate the company is exploring a mega sale of the asset. Divesting the orthopedics unit is an example of an addition-by-subtraction strategy. Orthopedics is a mature, lower-growth business compared with booming fields such as oncology and advanced cardiovascular therapies. Shedding this slower unit would improve overall revenue growth and margins. A sale could also generate a significant lump-sum payment — potentially billions — providing capital for acquisitions or share buybacks. Legal risks remain an important consideration. The company continues to face litigation over talc products, with a recent $1.5 billion verdict keeping the issue in headlines. A new commercial lawsuit from Bayer over prostate cancer drug marketing claims has added noise to the news cycle. Still, the stock's recent rally suggests the market is looking past these headlines. The prevailing bullish view is that Johnson & Johnson has the financial depth to manage liabilities without disrupting its business. With over $20 billion in cash and marketable securities, potential proceeds from an orthopedics sale and projected free cash flow of $21 billion, the company has a financial cushion capable of absorbing settlements. That financial strength keeps legal battles as balance-sheet items rather than existential threats to the dividend or operations. Capital Preservation With Upside Johnson & Johnson has evolved from a slow-moving conglomerate into a focused, high-tech healthcare company. By divesting its consumer health division (Kenvue (NYSE: KVUE)) and potentially its orthopedics unit, the company is streamlining to concentrate on high-growth opportunities in pharmaceuticals and medical technology. While the stock is no longer a bargain, trading near all-time highs, it offers a blend of capital preservation and growth that is hard to find elsewhere. The combination of a 64-year dividend growth streak, a low volatility profile and a clear path to $100 billion in revenue makes JNJ a compelling option for 2026. For investors fatigued by the unpredictability of the technology sector, Johnson & Johnson proves that, in the current market environment, boring can be both beautiful and profitable.
| 
